168 related articles for article (PubMed ID: 38058821)
1. Characteristics of the immune microenvironment associated with RRM2 expression and its application to PD-L1/PD-1 inhibitors in lung adenocarcinoma.
Lee SK; Hwang Y; Han JH; Haam S; Lee HW; Koh YW
Am J Cancer Res; 2023; 13(11):5443-5454. PubMed ID: 38058821
[TBL] [Abstract][Full Text] [Related]
2. Identification of CNKSR1 as a biomarker for "cold" tumor microenvironment in lung adenocarcinoma: An integrative analysis based on a novel workflow.
Cai Q; Peng M
Heliyon; 2024 Apr; 10(8):e29126. PubMed ID: 38628722
[TBL] [Abstract][Full Text] [Related]
3. The impact of CDCA5 expression on the immune microenvironment and its potential utility as a biomarker for PD-L1/PD-1 inhibitors in lung adenocarcinoma.
Koh YW; Hwang Y; Lee SK; Han JH; Haam S; Lee HW
Transl Oncol; 2024 Aug; 46():102024. PubMed ID: 38838437
[TBL] [Abstract][Full Text] [Related]
4. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death.
Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J
Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954
[TBL] [Abstract][Full Text] [Related]
5. Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma.
Koh YW; Park B; Jung SH; Han JH; Haam S; Lee HW
Front Immunol; 2023; 14():1137880. PubMed ID: 37033978
[TBL] [Abstract][Full Text] [Related]
6. Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma.
Gong Z; Jia Q; Chen J; Diao X; Gao J; Wang X; Zhu B
J Thorac Oncol; 2019 May; 14(5):857-866. PubMed ID: 30768970
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a ferroptosis-related gene to predict survival outcomes and the immune microenvironment in lung adenocarcinoma.
Deng B; Xiang J; Liang Z; Luo L
Cancer Cell Int; 2022 Sep; 22(1):292. PubMed ID: 36153508
[TBL] [Abstract][Full Text] [Related]
9. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
11. MAX transcriptionally enhances PD-L1 to inhibit CD8+ T cell-mediated killing of lung adenocarcinoma cells.
Huang D; Wang X; Qian Y; Wu J; Chen B; Zhang D; Dong F; Li Y
Cell Immunol; 2023 Apr; 386():104706. PubMed ID: 36931054
[TBL] [Abstract][Full Text] [Related]
12. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.
Yang P; He S; Ye L; Weng H
Int Arch Allergy Immunol; 2024 May; ():1-11. PubMed ID: 38781935
[TBL] [Abstract][Full Text] [Related]
13. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
14. H3K4me3-related lncRNAs signature and comprehensive analysis of H3K4me3 regulating tumor immunity in lung adenocarcinoma.
Fan T; Zhu M; Muhammad S; Xiao C; Li S; Tian H; Liu Y; Xue L; Zheng B; Li C; He J
Respir Res; 2023 May; 24(1):122. PubMed ID: 37131252
[TBL] [Abstract][Full Text] [Related]
15. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R
Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689
[TBL] [Abstract][Full Text] [Related]
16. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
[TBL] [Abstract][Full Text] [Related]
17. Cyclic adenosine monophosphate/phosphodiesterase 4 pathway associated with immune infiltration and PD-L1 expression in lung adenocarcinoma cells.
Tong L; Shan M; Zou W; Liu X; Felsher DW; Wang J
Front Oncol; 2022; 12():904969. PubMed ID: 35978822
[TBL] [Abstract][Full Text] [Related]
18. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
Front Genet; 2022; 13():1017866. PubMed ID: 36699466
[No Abstract] [Full Text] [Related]
20. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
